Matt Hoffman

Lisa Donahue PT, MPT, NCS, the director of Clinical Services at Evolution Devices, offered details about the EvoWalk platform, its potential in neurorehabilitation efforts, and its future clinical availability.

A study from the International Parkinson and Movement Disorder Society Virtual Congress suggest that despite protocol adherence, average costs are moderately high and vary significantly.

Deena Kuruvilla, MD, director, Westport Headache Institute, spoke to how the field and its related organizations might address the challenge of limited provider numbers, and what other efforts are required.

The FIGHT-PD study is expected to complete and read out interim results before the end of 2021. It aims to assess the exercise program’s safety, tolerability, and efficacy in Parkinson disease.

Patients who underwent deep brain stimulation procedures that were managed postoperatively in the home reported significantly fewer clinic visits with similar MDS-UPDRS scores to standard of care.

Deena Kuruvilla, MD, director, Westport Headache Institute, offered her insight into the trends in the clinical care of migraine and the effect that the pandemic has had on patients.

Data from MDS 2021 suggest that a 6-week brisk walking program can improve MDS-UPDRS nonmotor scores significantly compared to standard stretching interventions.

The combination drug of sodium phenylbutyrate–taurursodiol has been shown to functional decline in patients with amyotrophic lateral sclerosis compared with placebo in the phase 2/3 CENTAUR trial.

Get the latest news in neuromyelitis optica spectrum disorder, with data updates and expert insights, all in one place from the NeurologyLive team.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Deena Kuruvilla, MD.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

Two study authors provide commentary on data that suggests that offering clinicians more perspective into the individual patient experience can help inform care for those individuals with DRP.

Craig Martin, CEO, Global Genes, offered his inside perspective on the multistakeholder initiative and the fruits it hopes to bear for patients with rare CNS diseases.

Davis offered comments on the recent approval of brivaracetam (Birviact; UCB) as a treatment for pediatric patients with partial-onset seizures and its potential for these patients.

The global head of Neurodegeneration at Roche/Genentech offered her insights on additional analysis of the DIAN-TU trial of gantenerumab and perspectives on biomarker data.

Expert clinicians offer their perspectives on the upcoming IFN 2021 Congress, the impact of aducanumab, optic neuritis in NMOSD, cranial neuralgias, and miniature AD brain models.

AC Immune and Genentech announced that treatment with semorinemab, an investigational antitau antibody, in the phase 2 LAURIET study resulted in significant changes from baseline on ADAS-Cog11 scores.

Findings of the Salt Substitute and Stroke Study suggest a switch to salt substitute could reduce the risk of stroke by 13% in those with a history of hypertension or stroke.

Bruce Cree, MD, PhD, clinical research director of the UCSF Multiple Sclerosis Center, provided context on the status of patient education efforts and clinical development for neuromyelitis optica spectrum disorder.

MicroTransponder’s system is the first of its kind to be granted this indication, after supporting data from the VNS-REHAB trial suggested its efficacy in improving FMA-UE scores.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Adolfo Ramirez-Zamora, MD.

The toolkit’s assays contain several biomarkers, including Aß 1-42, Aß 1-40, α-syn, GFAP, IL-6, neurogranin, NfL, phosphotau181, S100B, sTREM2, total tau, and YKL-40.

The clinical research director of the UCSF Multiple Sclerosis Center shared his perspective on the history of clinical care for neuromyelitis optica spectrum disorder in light of 3 recent FDA approvals.

The long-acting C5 complement inhibitor, developed by Alexion and approved for atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria (PNH), failed to show an effect on ALSFRS-R score.

The full approval for BNT162b2 (Comirnaty; Pfizer/BioNTech) will afford physicians greater prescribing capability and is expected to play a role in driving workplace vaccine mandates.

This NeurologyLive® Peers & Perspectives series features experts in the diagnosis and treatment of Alzheimer disease discussing the recent approval of aducanumab, its implications for Alzheimer disease, and other promising therapies and diagnostic technologies in development.

After the FDA approval for Jazz Pharmaceuticals' oxybates combination therapy, Robert Iannone, MD, MSCE, offered insight into the potential effects the drug may have on the clinical care of patients with idiopathic hypersomnia.

Program chairs Fred D. Lublin, MD, and Stephen Silberstein, MD, offer insight into the third annual IFN meeting, which is set for September 17-18, 2021, to be held in a virtual setting.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Mitchell S.V. Elkind, MD, MS, MPhil.

The professor of brain science and director of the Chambers-Grundy Center for Transformative Neuroscience at UNLV spoke to the recently published HARMONY phase 3 study data.